Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine in the APPROACH study, which led to the Imbokodo and forthcoming Mosaico trails, prompted a robust immune response.
Researchers broke down the various strategies that the gay men in the Opposites Attract study used to prevent HIV transmission.
Biktarvy has a lower rate of adverse health events, according to 96-week data.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.
The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.
Published results have updated preliminary findings presented at a previous conference.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
HIV researcher David Alain Wohl, MD, urges AIDS activists to be a vanguard against indifference, overreach and shortsightedness.
Writer Anna Forbes responds to an open letter by HIV researcher David Alain Wohl, MD, that urges AIDS activists to do more.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.